1. CMU Intellectual Repository

Browsing by Author Breno R. Santos

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
or enter first few letters:  
Showing results 3 to 9 of 9 < previous 
Issue DateTitleAuthor(s)
1-Jan-2021Evaluation of phylogenetic methods for inferring the direction of human immunodeficiency virus (HIV) Transmission: HIV Prevention Trials Network (HPTN) 052Yinfeng Zhang; Chris Wymant; Oliver Laeyendecker; M. Kathryn Grabowski; Matthew Hall; Sarah Hudelson; Estelle Piwowar-Manning; Marybeth McCauley; Theresa Gamble; Mina C. Hosseinipour; Nagalingeswaran Kumarasamy; James G. Hakim; Johnstone Kumwenda; Lisa A. Mills; Breno R. Santos; Beatriz Grinsztejn; Jose H. Pilotto; Suwat Chariyalertsak; Joseph Makhema; Ying Q. Chen; Myron S. Cohen; Christophe Fraser; Susan H. Eshleman
15-Apr-2018HIV Drug Resistance in Adults Receiving Early vs. Delayed Antiretroviral Therapy: HPTN 052Philip J. Palumbo; Jessica M. Fogel; Sarah E. Hudelson; Ethan A. Wilson; Stephen Hart; Laura Hovind; Estelle Piwowar-Manning; Carole Wallis; Maria A. Papathanasopoulos; Mariza G. Morgado; Shanmugam Saravanan; Srikanth Tripathy; Joseph J. Eron; Joel E. Gallant; Marybeth McCauley; Theresa Gamble; Mina C. Hosseinipour; Nagalingeswaran Kumarasamy; James G. Hakim; Jose H. Pilotto; Johnstone Kumwenda; Victor Akelo; Sheela V. Godbole; Breno R. Santos; Beatriz Grinsztejn; Ravindre Panchia; Suwat Chariyalertsak; Joseph Makhema; Sharlaa Badal-Faesen; Ying Q. Chen; Myron S. Cohen; Susan H. Eshleman
26-Sep-2019Phylogenetic Methods Inconsistently Predict the Direction of HIV Transmission Among Heterosexual Pairs in the HPTN 052 CohortRebecca Rose; Matthew Hall; Andrew D. Redd; Susanna Lamers; Andrew E. Barbier; Stephen F. Porcella; Sarah E. Hudelson; Estelle Piwowar-Manning; Marybeth McCauley; Theresa Gamble; Ethan A. Wilson; Johnstone Kumwenda; Mina C. Hosseinipour; James G. Hakim; Nagalingeswaran Kumarasamy; Suwat Chariyalertsak; Jose H. Pilotto; Beatriz Grinsztejn; Lisa A. Mills; Joseph Makhema; Breno R. Santos; Ying Q. Chen; Thomas C. Quinn; Christophe Fraser; Myron S. Cohen; Susan H. Eshleman; Oliver Laeyendecker
11-Aug-2011Prevention of HIV-1 infection with early antiretroviral therapyMyron S. Cohen; Ying Q. Chen; Marybeth McCauley; Theresa Gamble; Mina C. Hosseinipour; Nagalingeswaran Kumarasamy; James G. Hakim; Johnstone Kumwenda; Beatriz Grinsztejn; Jose H.S. Pilotto; Sheela V. Godbole; Sanjay Mehendale; Suwat Chariyalertsak; Breno R. Santos; Kenneth H. Mayer; Irving F. Hoffman; Susan H. Eshleman; Estelle Piwowar-Manning; Lei Wang; Joseph Makhema; Lisa A. Mills; Guy De Bruyn; Ian Sanne; Joseph Eron; Joel Gallant; Diane Havlir; Susan Swindells; Heather Ribaudo; Vanessa Elharrar; David Burns; Taha E. Taha; Karin Nielsen-Saines; David Celentano; Max Essex; Thomas R. Fleming
1-Sep-2019Third-line antiretroviral therapy in low-income and middle-income countries (ACTG A5288): a prospective strategy studyBeatriz Grinsztejn; Michael D. Hughes; Justin Ritz; Robert Salata; Peter Mugyenyi; Evelyn Hogg; Linda Wieclaw; Robert Gross; Catherine Godfrey; Sandra W. Cardoso; Aggrey Bukuru; Mumbi Makanga; Sharlaa Faesen; Vidya Mave; Beatrice Wangari Ndege; Sandy Nerette Fontain; Wadzanai Samaneka; Rode Secours; Marije van Schalkwyk; Rosie Mngqibisa; Lerato Mohapi; Javier Valencia; Patcharaphan Sugandhavesa; Esmelda Montalban; Anchalee Avihingsanon; Breno R. Santos; Nagalingeswaran Kumarasamy; Cecilia Kanyama; Robert T. Schooley; John W. Mellors; Carole L. Wallis; Ann C. Collier; B. Grinsztejn; P. N. Mugyenyi; A. Collier; R. Salata; C. Godfrey; E. Hogg; M. Hughes; J. Ritz; L. Wieclaw; T. Sise; J. W. Mellors; C. Wallis; C. V. Fletcher; M. Gandhi; R. Gross; R. T. Schooley; R. Walensky; M. van Schalkwyk; S. Faesen; R. Mngqibisa; J. Valencia; E. Montalban; N. Kumarasamy; C. Kanyama; S. W. Cardoso; B. R. Santos; B. Mansfield; H. Mugerwa; B. W. Ndege; R. Secours; W. Samaneka; D. Kadam; V. Mave; M. Makanga; S. N. Fontain; P. Sugandhavesa; A. Avihingsanon; L. Nakibuuka; H. Nassolo; P. Anthony; V. Kulkarni; M. Nsubuga; J. van Wyk; J. Rooney; Y. van Delft; R. Leavitt; R. Luk; A. Benns; L. Hovind; A. Shahkolahi
1-Jun-2022Third-line antiretroviral therapy, including raltegravir (RAL), darunavir (DRV/r) and/or etravirine (ETR), is well tolerated and achieves durable virologic suppression over 144 weeks in resource-limited settings: ACTG A5288 strategy trialAnchalee Avihingsanon; Michael D. Hughes; Robert Salata; Catherine Godfrey; Caitlyn McCarthy; Peter Mugyenyi; Evelyn Hogg; Robert Gross; Sandra W. Cardoso; Aggrey Bukuru; Mumbi Makanga; Sharlaa Badal-aesen; Vidya Mave; Beatrice Wangari Ndege; Sandy Nerette Fontain; Wadzanai Samaneka; Rode Secours; Marije Van Schalkwyk; Rosie Mngqibisa; Lerato Mohapi; Javier Valencia; Patcharaphan Sugandhavesa; Esmelda Montalban; Cornelius Munyanga; Maganizo Chagomerana; Breno R. Santos; Nagalingeswaran Kumarasamy; Cecilia Kanyama; Robert T. Schooley; John W. Mellors; Carole L. Wallis; Ann C. Collier; Beatriz Grinsztejn
15-Nov-2013Undisclosed antiretroviral drug use in a multinational clinical trial (HIV prevention trials network 052)Jessica M. Fogel; Lei Wang; Teresa L. Parsons; San San Ou; Estelle Piwowar-Manning; Ying Chen; Victor O. Mudhune; Mina C. Hosseinipour; Johnstone Kumwenda; James G. Hakim; Suwat Chariyalertsak; Ravindre Panchia; Ian Sanne; Nagalingeswaran Kumarasamy; Beatriz Grinsztejn; Joseph Makhema; Jose Pilotto; Breno R. Santos; Kenneth H. Mayer; Marybeth McCauley; Theresa Gamble; Namandjé N. Bumpus; Craig W. Hendrix; Myron S. Cohen; Susan H. Eshleman
Showing results 3 to 9 of 9 < previous